Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2022

Genmab — December 2022

Planlagt Fastgjort Låst Flyttet Genmab
668 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #159

    https://www.youtube.com/watch?v=8yirKYro2cw talquetamab

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #160

      Just a moment...

      favicon

      (www.proinvestor.com)

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #161

        @Bulder. Jan will probably say it is a Janssen product, and refer the analyst to them.

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #162

          Also talq had 2 deaths due to covid. Maybe this problem will be solved when covid is over.

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #163

            GB: I think they should discuss the general issue with risk of infections and bispecifics.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #164

              at the same time, according to Dr Chari: “If you measure Covid antibodies, patients on [talquetamab] are producing antibodies. That’s a really different signal than what we’ve seen before.”

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #165

                Ye s, but as he says, it is tragic to loose a cr- patient to covid. I would like to hear if they can come up with something to avoid infections.

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #166

                  Does anybody know when hex38 will be presented.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #167

                    tonight https://ash.confex.com/ash/2022/webprogram/Paper159116.html

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #168

                      but it is a poster, so you have to hope someone will post something on twitter, we'll probably have to wait for the R&D

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #169

                        rest of the schedule by the way: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #170

                          ASH tråd. Fyld gerne på: https://www.proinvestor.com/boards/108608/

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #171

                            Rafineret teknologi viser gode resultater. Dejligt med de mange fremskridt i cancerbehandling https://www.bbc.com/news/health-63859184

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #172

                              Ham her har visse indvendinger imod talq-studiet: https://www.youtube.com/watch?v=PAvLpjVstOk

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #173

                                Den første del af kritikken er svært for lægmand at vurdere. Håber at nogen af vore eksperter kan byde ind. Det med det uetiske med den homøopatiske dosering i lavdosisgruppen er til gengæld nemt for de fleste at forstå og være enig i. Det er jeg i hvert fald.

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #174

                                  Han er i hvert fald ikke begejstret for car-t. Og så peger han også på bivirkninger. Infektioner af tec og udslet på huden af talq. Men som han selv siger, der er en pris at betale. Om man skulle gå direkte til randomiserede studier fra fase 1, kan jeg ikke vurdere. Men hvis det var muligt, ville fda vel have krævet det.

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    peter12
                                    wrote on sidst redigeret af
                                    #175

                                    Prasad er vist en lidt kontroversiel person https://tuftsdaily.com/news/2022/03/08/controversial-oncologist-dr-vinay-prasad-disavowed-by-dean-lectures-to-gsbs/

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #176

                                      Epcoritamab+RDHAX/C: quickly effective and well tolerated in rrDLBCL in the EPCORE NHL-2 study https://twitter.com/amniebla/status/1601982162168954882?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        GeorgeBest
                                        wrote on sidst redigeret af
                                        #177

                                        Epcoritamab CD20×CD3 with DHAX, n=29, 66% primary refractory, 21 pts responded and 16 proceeded to AutoSCT, ORR 85%, 67% CR https://twitter.com/abhinav_deol/status/1601981658252836866?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #178

                                          sc Epcoritamab+R-DHAC/X
                                          in RR DLBCL ASCT eligible
                                          Ph 1/2
                                          N=29 58y (28-75)
                                          16 pts had ASCT after 3 cycles
                                          5 continued epco without ASCT

                                          CR 81% in ASCT pts 45% in no ASCT
                                          Short Fu 12.6 mo PFS NR

                                          V active combo (more than Pola-RICE) https://twitter.com/pallawitorkamd/status/1601981858778329088?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper